Does Raised 2026 Outlook Change The Bull Case For Johnson & Johnson (JNJ)?

Johnson & Johnson reported third quarter 2026 sales of US$25,399 million and net income of US$210 million, raised its full year outlook, and affirmed a US$1.34 per share fourth quarter dividend payable in December 2026. Strong demand for TREMFYA, early momentum for ICOTYDE, and continued focus on oncology helped offset weaker MedTech performance and international pricing pressure for Johnson & Johnson. We will look at how Johnson & Johnson's raised 2026 guidance, despite softer MedTech...